-
FBR Initiates Fidelity Southern At Market Perform; Says Shares Reflect Mortgage Banking, Indirect Auto Loans
Wednesday, May 18, 2016 - 10:40am | 272Read More...Fidelity Southern Corporation (NASDAQ: LION) shares have plunged 30 percent since January 4. FBR & Co’s Christopher Nolan initiated coverage of the company with a Market Perform rating and a price target of $18. The analyst commented that shares now reflect mortgage banking and indirect...
-
Icahn's $7/Share Federal-Mogul Offer Is Conservative, Analyst Says
Tuesday, March 1, 2016 - 8:17am | 251Read More...FBR & Co’s Christopher Van Horn maintained a Market Perform rating for Federal-Mogul Holdings Corp (NASDAQ: FDML), while reducing the price target from $9 to $7, after the company announced its FY15 and 4Q15 results, and announced that it had received an offer from Icahn Enterprises LP...
-
More Mortgage REIT Consolidation Is On The Table
Monday, February 29, 2016 - 11:06am | 308Read More...Following last week’s announced deal between Apollo Commercial Real Est. Finance Inc (NYSE: ARI) and Apollo Residential Mortgage Inc (NYSE: AMTG), FBR & Co analyst Daniel Atscher released a new report discussing the potential for further consolidation within the mortgage REIT space....
-
FBR Encouraged By NXP Semiconductors Positive Results And Guidance, Reiterates Top Pick Status
Thursday, February 4, 2016 - 8:16am | 358Read More...NXP Semiconductors NV (NASDAQ: NXPI) shares have plunged 16 percent since January 4. FBR & Co’s Christopher Rolland maintained an Outperform rating for the company, with a price target of $105. The company’s results and guidance were better than feared, and the company...
-
Tim Cook 'Ripped The Band-Aid' Off Apple's Guidance
Wednesday, January 27, 2016 - 7:27am | 405Read More...Despite a slight recovery over the last few trading days, shares of Apple Inc. (NASDAQ: AAPL) have lost 7 percent since December 28. FBR & Co’s Daniel H. Ives maintained an Outperform rating for the company, while reducing the price target from $150 to $130. While Apple’s...
-
Zafgen Doubles: What Do The Experts Think?
Thursday, January 21, 2016 - 11:51am | 388Read More...Recently, analysts from FBR & Co. and RBC Capital Markets gave their take on Zafgen Inc (NASDAQ: ZFGN) after the company's stock price soared on news that their beloranib drug had positive Phase III data. RBC Capital Markets upgraded Zafgen from Sector Perform to Outperform and raised their...
-
FBR Upgrades Kite Pharma, Sees 35% Upside
Tuesday, January 19, 2016 - 10:05am | 308Read More...Kite Pharma Inc (NASDAQ: KITE) shares have lost 16 percent since October 20. FBR & Co’s Ed White upgraded the rating for the company from Market Perform to Outperform, while raising the price target from $72 to $75. Kite Pharma’s impressive performance in 2015 could...
-
The Best Names To Play In Next-Gen Cybersecurity...
Wednesday, January 6, 2016 - 8:20am | 509Read More...Shares of Palo Alto Networks Inc (NYSE: PANW), Check Point Software Technologies Ltd. (NASDAQ: CHKP) and Proofpoint Inc (NASDAQ: PFPT) have been under pressure over the past month. FBR & Co’s Daniel H. Ives expressed optimism regarding cybersecurity demand into 2016. Ives...
-
FBR: Apple Growth Fears 'Overblown'
Monday, January 4, 2016 - 10:00am | 299Read More...Apple Inc. (NASDAQ: AAPL) shares have lost 19 percent in the last six months. FBR & Co’s Daniel H. Ives maintained an Outperform rating for the company. Concerns over China’s growth and softer-than-expected demand for the iPhone 6s appear overblown, Ives stated. Apple...
-
Notable Tech Analyst Highlights Top 10 M&A Marriages For '16
Wednesday, December 30, 2015 - 9:34am | 614Read More...FBR & Co’s Daniel H. Ives said that the Software sector could be characterized by M&A, growth and cloud spending in 2016. Next-gen technology vendors seem to be the winners, at the expense of traditional tech vendors, Ives added. Analyst Daniel Ives said that investor...
-
Here's What Wall Street Thinks Of Chimerix After The Crash
Tuesday, December 29, 2015 - 10:12am | 357Read More...Chimerix Inc (NASDAQ: CMRX) shares were crushed on Monday, as the stock fell more than 80 percent following news that its brincidofovir SUPPRESS study fell short of endpoint expectations in the prevention of cytomegalovirus (CMV) infection. After the big fall, is it time to stick a fork in Chimerix...
-
Why This Notable Analyst Reduced iPhone Estimates Across The Board
Wednesday, December 23, 2015 - 7:04am | 299Read More...Apple Inc. (NASDAQ: AAPL) shares have lost 10 percent in the last month, slipping below the $110 mark on December 17. FBR & Co’s Daniel H. Ives maintained an Outperform rating on the company, while reducing the price target from $175 to $150. Although Apple has the opportunity...
-
What Wall Street Is Saying Ahead Of Oracle's Earnings Call
Wednesday, December 16, 2015 - 3:05pm | 414Read More...Oracle Corporation (NYSE: ORCL) is scheduled to announce its second quarter fiscal 2016 financial results after the market closes on Wednesday. Ahead of the report, a few major Wall Street research firms shared their previews of the results. According to Estimize, the Street is modeling...
-
4 Questions Apple Must Answer
Thursday, December 10, 2015 - 8:27am | 623Read More...Apple Inc. (NASDAQ: AAPL) shares have been volatile in 2015, and are down 4 percent since November 10. FBR & Co’s Daniel H. Ives maintained an Outperform rating on the company, with a price target of $175. Ives addressed the potential of Apple Watch, Apple’s size,...
-
Apple's Christmas List? Adobe, Box, GoPro And Maybe Even Tesla
Thursday, December 10, 2015 - 7:52am | 674Read More...Apple Inc. (NASDAQ: AAPL) shares are down 4 percent in the last month, and are trading meaningfully below their 52-week high of $134.54. FBR & Co’s Daniel H. Ives maintained an Outperform rating on the company, with a price target of $175. Ives commented on potential M&A...
